Eleonora Teplinsky: New ASCO guidelines are out for genetic testing for people with breast cancer

Eleonora Teplinsky shared on LinkedIn:

“New ASCO guidelines are out for genetic testing for people with breast cancer!

• BRCA 1/2 mutation testing should be offered to ALL newly diagnosed patients with breast cancer ≤65 years which is the biggest change.
• BRCA 1/2 mutation testing should be offered for those >65 years based on personal and family history, ancestry, male sex at birth, presence of triple negative breast cancer, and eligibility for PARP inhibitor therapy. (PARP inhibitors used for high risk TNBC or HR+/HER2- disease in patients w BRCA mutations- there are specific criteria).
• All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/2 testing, regardless of family history.
• BRCA1/2 testing should be offered to women who develop a second primary cancer in the ipsilateral or contralateral breast.
•  For patients with a prior history of breast cancer and without active disease, testing should be offered to patients diagnosed ≤65 years and selectively in patients diagnosed after 65 years, if it will inform personal and family risk.
• Testing for other genes that increase breast cancer risk such as PALB2, CHEK2, ATM should be offered to those based on family and personal history.
• Patients should have access to genetic counselling. Variants of unknown significance should be followed but should not change management.These guidelines will allow more people access to genetic testing which I think is huge. Let me know what questions you have about genetic testing and these new guidelines!”

Proceed to video attached to the post.

Source: Eleonora Teplinsky/LinkedIn

Eleonora Teplinsky is a medical oncologist specializing in breast and gynecologic oncology. She is the head of breast and gynecological medical oncology at Valley-Mount Sinai Comprehensive Cancer Care in Paramus, New Jersey, and a clinical assistant professor of medicine at the Icahn School of Medicine at Mount Sinai in New York.

Her clinical and research interests focus on young women with breast cancer, survivorship, exercise oncology, and the use of social media in oncology. She is passionate about oncology education and advocacy on social media and is the host of the INTERLUDE Podcast, where she shares the stories and experiences of those who have been affected by cancer.

Dr. Teplinsky is the co-lead of the The Collaboration for Outcomes using Social Media in Oncology (COSMO) – a social media lab working to provide a venue for social media research in oncology.